Prodotti Chirurgia Vascolare

Una linea di Prodotti studiata per fornire un delicato approccio al trattamento di Infiammazioni e Infezioni vascolari, per la cura e il trattamento sistemico e topico dell’Insufficienza circolatoria, microcircolatoria, stasi venosa, edemi, delle Ulcere e del Piede diabetico.

Tutti i prodotti di questa linea sono costituiti da un’associazione di principi attivi e dosaggi ottimali per garantire un rapido effetto terapeutico.








RSS Journal of Vascular Surgery

  • Emergent Repair of Ruptured Juxtarenal Abdominal Aortic Aneurysm With Antegrade In Situ Laser Fenestration is Feasible; How to Do It? Aprile 1, 2024
    Emergent repair of a juxta-renal abdominal aortic aneurysm (JAAA) for rupture is challenging in the absence of an off-the-shelf device. Parallel grafting can be complicated by type 1a endoleak, while using physician-modified endografts can be time consuming. We present a technique for antegrade in-situ laser fenestration for the emergent repair of ruptured JAAA.
    Alyssa Kessel, Thekla Bacharach, Anand Dayama
  • Senza titolo Aprile 1, 2024
    Once again, the annual meeting of the Associate Faculty (AF) at the VEITHsymposium achieved its intended goals. Another record number of abstract submissions from many parts of the world was achieved. These abstracts, covering various topics in the diagnosis and management of vascular diseases, were distributed among several sessions to allow a more intimate discussion […]
    Enrico Ascher, Frank J. Veith
  • Predictors of Failure to Rescue After Fenestrated-Branched Endovascular Aortic Repair of Thoracoabdominal Aortic Aneurysms Aprile 1, 2024
    Failure to rescue (FTR) is defined as any mortality from an in-hospital complication and has been shown to be an important differentiating factor among centers performing complex operations. The study aimed to assess incidence and predictors for FTR among centers performing fenestrated-branched endovascular aortic repair (FB-EVAR) of thoracoabdominal aortic aneurysms (TAAAs).
    Andrea Vacirca, Thomas Mesnard, Ying Huang, Bernardo C. Mendes, Tomasz Jakimowicz, Darren B. Schneider, Stéphan Haulon, Jonathan Sobocinski, Adam W. Beck, Andres Schanzer, Mark A. Farber, Carlos Timaran, Andrea Kahlberg, Tilo Kölbel, Gustavo S. Oderich
  • Iliocaval Occlusion – Endovascular Approach With IVUS and Cone Beam Computed Tomography Aprile 1, 2024
    Iliocaval occlusions can be severely disabling, having an impact on patients’ daily activities. With the improvement of dedicated venous stents, and the evolution of the technique, the endovascular approach is now considered the best option.
    Nelson Camacho, Sérgio Silva
  • A 10-Year Experience in Managing Mycotic Aorto-iliac Aneurysms Aprile 1, 2024
    Mycotic aneurysms hold a high risk of rupture with a peri-operative mortality rate of up to 44%. The aim is to describe the outcomes and management of mycotic aortic, iliac or lower limb arterial aneurysms over 10 years in an Australian quaternary hospital.
    Stacey Telianidis, Michelle Ng, George Matalanis, Jason Chuen
  • Effects of a Person-Centered, Nurse-Led Follow-Up Program on Adherence to Prescribed Medication Among Patients Surgically Treated for Intermittent Claudication: A Randomized Clinical Trial Aprile 1, 2024
    Sara T Haile, Eva Joelsson-Alm, Unn Britt Johansson, Helena Lööf, Ulrika Palmer-Kazen, Peter Gillgren, Anneli Linné. Effects of a person-centred, nurse-led follow-up programme on adherence to prescribed medication among patients surgically treated for intermittent claudication: randomized clinical trial. British Journal of Surgery, 2022;109(9):846–856. https://doi.org/10.1093/bjs/znac241
    Sara T. Haile
  • Severe Intermittent Claudication. Medical Treatment or Primary Percutaneous Intervention? Aprile 1, 2024
    Excellent outcomes in patients with intermittent claudication can be achieved with exercise therapy and optimal medical management. The objective of this study was to demonstrate that medical treatment is useful in improving severe intermittent claudication (Rutherford 3/Fontaine IIB) in patients with peripheral vascular disease, without primary percutaneous interventions.
    Juan I. Pardo, Daniel Paliza, Lisandro Carnero, Sergio Palomeque, Ana Mollon